Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 4, 2004, Pages 551-554

  Bounameaux, H ^a   De Moerloose, P ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIDOTE; ANTIHYPERTENSIVE AGENT; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 10A; CYCLOSPORIN; DALTEPARIN; DIGOXIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PENICILLIN DERIVATIVE; PLASMA PROTEIN; PROTAMINE; TINZAPARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD SAMPLING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG OVERDOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG USE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LABORATORY TEST; META ANALYSIS; PHARMACODYNAMICS; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; PROTHROMBIN TIME; RECURRENCE RISK; SIDE EFFECT; THROMBOEMBOLISM; THROMBOSIS; VENOUS THROMBOEMBOLISM; BLOOD; NOTE; PARTIAL THROMBOPLASTIN TIME; PRACTICE GUIDELINE; RISK;

ANTICOAGULANTS; DRUG MONITORING; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PARTIAL THROMBOPLASTIN TIME; PRACTICE GUIDELINES; RISK; THROMBOEMBOLISM;

EID: 3242678141     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7933.2004.00648.x     Document Type: Article

References (17)

1. Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287: 324-7.
2. Raschke R, Hirsh J, Guidry JR. Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin. Ann Intern Med 2003; 138: 720-3.
3. Anand S, Yusuf S, Pogue J, Ginsberg J, Hirsh J. Relationship of activated partial thromboplastin time to coronary events and bleeding events in patients with acute coronary events who receive heparin. Circulation 2003; 107: 2884-8.
4. Greaves M. Limitations of the laboratory monitoring of heparin therapy. Thromb Haemost 2002; 87: 163-4.
5. Kitchen S, Lampietro R, Wooley AM, Preston FE. Anti-Xa monitoring during treatment of LMWH or danaparoid: inter-assay variability. Thromb Haemost 1999; 82: 1289-93.
6. Kovacs MJ, Keeney M, MacKinnon K, Boyle E. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight or unfractionated heparin. Clin Lab Haematol 1999; 21: 55-60.
7. Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, Kher A, Aiach M, Fiessinger JN. Adjusted versus fixed doses of the low-molecular-weight heparin Fragmin in the treatment of deep vein thrombosis. Thromb Haemost 1994; 71: 698-702.
8. DVTENOX Study Group. Markers of hemostatic system activation in acute deep vein thrombosis - evolution during the first days of heparin treatment. Thromb Haemost 1993; 70: 909-14.
9. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130: 800-9.
10. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism. Am J Med 1996; 100: 269-77.
11. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991; 78: 2337-43.
12. Sephton V, Farquharson RG, Topping J, Quenby SM, Cowan C, Back DJ, Toh CH. A longitudinal study of maternal dose-response to low molecular weight heparin in pregnancy. Obstet Gynecol 2003; 101 1307-11.
13. Sutor A, Massiccotte P, Leaker M, Andrew M. Heparin therapy in pediatric patients. Semin Thromb Hemost 1997; 23: 303-19.
14. Massicotte P, Julian JA, Gent M, Shields K, Marzinotto V, Szechtman B, Andrew M; REVIVE Study Group. An open-label randomized trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res 2003; 109: 85-92.
15. Mismetti P, Laporte-Simitsidis S, Navarro C, Sie P, d'Azemar P, Necciari J, Duret JP, Gaud C, Decousus H, Boneu B. Aging and venous thromboembolism influence on pharmacodynamics of the anti-Xa and anti-IIa activities of a low-molecular weight heparin (nadroparin). Thromb Haemost 1998; 79: 1162-5.
16. Siguret V, Pautas E, Fevrier M, Wipff C, Durand-Gasselin B, Laurent M, Andreux JP, d'Urso M, Gaussem P. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa U/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 2000; 84 800-4.
17. Nagge J, Crowther M, Hirsh J. Is impaired renal function a contra-indication to the use of low-molecular-weight heparin? Arch Intern Med 2002; 162: 2605-9.